ABBV vs NVO

AbbVie and Novo Nordisk A/S, both Healthcare

AbbVie is the larger company at $382B against $191B. Over the past year ABBV returned +37% against +1.5% for NVO. Ryufin's sector-relative Smart Score puts NVO ahead, 9/10 against 6/10.

AbbVie and Novo Nordisk A/Scompared on valuation, return and Ryufin’s Smart Score
Figure	ABBV	NVO
Last close	$263	$47.19
Market cap	$382B	$191B
Trailing P/Elower is cheaper for the same earnings, not automatically better	74.3	n/a
Dividend yield	2.5%	n/a
1-year return	+37%	+1.5%
5-year return	+170%	+13%
Ryufin Smart Scoresector-relative, 1–10	6/10	9/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

AbbVie

Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.

ABBV overview revenue and segments valuation

Novo Nordisk A/S

NVO overview revenue and segments valuation

Open these two in the interactive comparison to add more names, change the period or read the correlation.